AMAG Pharmaceuticals Articles

Positive opinions from CHMP for Forxiga, Jakavi, Rienso and Flutiform but not Glybera

22 April 2012

Rainbow Coral seeks place in $84.6 billion biotechnology sector, forming new division; AMAG merger with Allos called off

23 October 2011

Allos looks to complete merger with AMAG, as third party bows out

11 October 2011

US deal for Vectura; takeover bid for AMAG

3 August 2011

AMAG Pharma and Allos Thera to merge in $686 million stock deal; Express Scripts to buy Medco

21 July 2011

Takeda buys rights to AMAG Pharma’s Feraheme in select ex-US territories, including Europe, for up to $280 million; and R113675 in Japan from J&J

6 April 2010

Showing 1-6 of 6 articles

Go to beginning

Previous

1

Next

Go to end